| Literature DB >> 25861469 |
Wantanee Kriengsinyos1, Ajima Wangtong1, Surat Komindr2.
Abstract
This study's aim was to test the low-density lipoprotein cholesterol- (LDL-c-) lowering efficacy of biscuits containing 2 g of plant stanols, which corresponded to 3.4 g of plant stanol esters. The biscuit is a new food format that can be consumed as a snack. In a double-blind, placebo-controlled parallel design study, 119 mildly to moderately hypercholesterolemic volunteers were randomized to plant stanol or control groups. Subjects were comparable in age, gender, lipid profiles, and body mass index. They consumed a control biscuit once a day for a two-week period, followed by a four-week intervention period that either had a plant stanol ester biscuit or a control. During the habitual diet, one biscuit per day was consumed at any time that subjects wished. Serum lipid profiles were measured at the first day of run-in, at baseline, and at the study's end. Compared to the control, the total cholesterol (TC), LDL-c, and the LDL-to-high-density lipoprotein (LDL/HDL) ratio had serum reductions of 4.9%, 6.1%, and 4.3%, respectively, and were observed after 4 weeks of biscuit consumption with added plant stanols (P < 0.05). A significantly higher reduction in LDL-c (8.9%) and LDL/HDL ratio (11.4%) was measured in those taking a plant stanol biscuit with a meal compared to those who consumed a plant stanol biscuit without other food. In conclusion, incorporating plant stanols into a biscuit is an attractive, convenient, and acceptable way to modestly lower elevated cholesterol concentrations. For optimal efficacy, biscuits should be consumed with a meal as part of a healthy diet.Entities:
Year: 2015 PMID: 25861469 PMCID: PMC4377436 DOI: 10.1155/2015/353164
Source DB: PubMed Journal: Cholesterol ISSN: 2090-1283
Nutritive values of the placebo and plant stanol fortified biscuits.
| Nutritional values/biscuit (28 g) | Intervention biscuits | Control biscuits | ||
|---|---|---|---|---|
| Chocolate | Fruity | Chocolate | Fruity | |
| Energy (kJ) | 504 | 498 | 519 | 518 |
| Protein (g) | 2.2 | 2.4 | 2.3 | 2.5 |
| Carbohydrates (g) | 16.0 | 15.7 | 16.4 | 16.4 |
| Of which sugars | 5.7 | 5.9 | 5.5 | 5.5 |
| Fat (g) | 4.9 | 4.8 | 4.9 | 4.8 |
| Of which saturated fatty acids | 0.8 | 0.7 | 0.9 | 0.8 |
| Of which monounsaturated fatty acids | 2.6 | 2.6 | 2.5 | 2.5 |
| Of which polyunsaturated fatty acids | 1.3 | 1.2 | 1.2 | 1.3 |
| Of which trans fatty acids | 0.1 | 0.1 | 0.0 | 0.0 |
| Plant stanols (g)* | 1.92 | 1.92 | 0.0 | 0.0 |
| Fiber (g) | 1.5 | 1.8 | 2.4 | 2.4 |
*Composition: 83% sitostanol and 17% campestanol.
Baseline demographic of the mild hypercholesterolemic subjects in the control and plant stanol groups1.
|
Control | Plant stanol | |||
|---|---|---|---|---|
| Total | Biscuit with meal | Biscuit without meal | ||
| ( | ( | ( | ||
| Gender (male/female) | 14/46 | 15/44 | 12/21 | 3/23 |
| Age (years) | 42.2 ± 9.5 | 42.9 ± 9.3 | 41.5 ± 9.0 | 43.3 ± 9.6 |
| Weight (kg) | 61.8 ± 11.8 | 62.3 ± 14.3 | 63.6 ± 15.0 | 60.6 ± 13.3 |
| Height (cm) | 158.8 ± 8.1 | 158.8 ± 8.0 | 160.2 ± 7.9 | 157.1 ± 7.8 |
| BMI (kg/m2) | 24.7 ± 8.5 | 25.4 ± 11.3 | 24.7 ± 4.9 | 24.5 ± 4.6 |
| Cholesterol (mmol/L) | ||||
| Total cholesterol | 6.01 ± 0.62 | 6.02 ± 0.78 | 6.26 ± 0.74 | 5.72 ± 0.73 |
| LDL-cholesterol | 4.13 ± 0.60 | 4.12 ± 0.75 | 4.37 ± 0.74 | 3.81 ± 0.65 |
| HDL-cholesterol | 1.59 ± 0.46 | 1.58 ± 0.34 | 1.56 ± 0.32 | 1.62 ± 0.37 |
| Total cholesterol : HDL ratio | 4.08 ± 1.20 | 3.96 ± 0.92 | 4.17 ± 0.93 | 3.69 ± 0.83 |
| LDL : HDL ratio | 2.84 ± 0.97 | 2.74 ± 0.80 | 2.93 ± 0.81 | 2.49 ± 0.74 |
| Triglyceride | 1.40 ± 0.69 | 1.37 ± 0.56 | 1.33 ± 0.59 | 1.42 ± 0.52 |
1Values are means ± SD. To convert mmol/L of cholesterol and triglyceride to mg/dL, multiply by 39 and 89, respectively.
Energy and nutrient intakes of the mild hypercholesterolemic subjects during the study between control and plant stanol groups1.
| Nutrients | Control group | Plant stanol group | ||||
|---|---|---|---|---|---|---|
| Week 0 | Week 2 | Week 6 | Week 0 | Week 2 | Week 6 | |
| Energy (MJ) | 5.6 ± 2.0 | 5.6 ± 2.0 | 5.6 ± 2.0 | 5.7 ± 2.0 | 5.7 ± 2.0 | 5.7 ± 2.1 |
| Carbohydrate (g/d) | 172.8 ± 60.0 | 173.0 ± 60.0 | 174.8 ± 60.5 | 184.1 ± 76.7 | 183.2 ± 75.4 | 180.7 ± 76.2 |
| Protein (g/d) | 54.3 ± 24.9 | 53.3 ± 25.2 | 54.2 ± 26.3 | 53.9 ± 21.4 | 52.4 ± 22.0 | 52.8 ± 22.6 |
| Fat (g/d) | 50.4 ± 25.2 | 50.2 ± 25.7 | 50.0 ± 25.9 | 46.9 ± 21.9 | 47.4 ± 22.0 | 47.2 ± 22.0 |
| Dietary fiber (g/d) | 9.8 ± 4.6 | 9.8 ± 4.5 | 9.9 ± 4.7 | 9.8 ± 5.2 | 9.5 ± 5.2 | 9.6 ± 5.1 |
| Cholesterol (mg/d) | 237.5 ± 57.6 | 235.7 ± 59.4 | 234.9 ± 60.4 | 237.9 ± 57.8 | 238.8 ± 58.5 | 239.0 ± 59.0 |
| Energy distribution | ||||||
| Carbohydrate (%) | 51.8 ± 9.6 | 52.2 ± 9.9 | 52.3 ± 10.5 | 53.5 ± 10.7 | 53.5 ± 10.5 | 53.4 ± 10.2 |
| Fat (%) | 32.3 ± 7.8 | 32.2 ± 8.1 | 32.0 ± 8.5 | 30.7 ± 8.3 | 31.0 ± 8.2 | 30.9 ± 7.8 |
| Protein (%) | 15.9 ± 4.6 | 15.6 ± 4.5 | 15.8 ± 4.8 | 15.8 ± 4.7 | 15.6 ± 4.5 | 15.7 ± 4.4 |
1Values are means ± SD. Week 0 (run in); week 2 (baseline); week 6 (end of intervention); no significant difference in all nutrient intakes between two groups at baseline, week 2 and week 6, by repeated measure analysis of variance.
Figure 1The percentage change in total, LDL, HDL, and LDL/HDL ratio and triglyceride concentrations from baseline comparing between control and stanol groups (mean ± SEM), (a) total subjects; (b) subgroup: subjects consumed a biscuit with meal; (c) subgroup: subjects consumed a biscuit alone (without meal). * P < 0.01 significantly different from control group.
Changes in lipid profiles between control and stanol groups (for all subjects and subgroups of subjects who consume a biscuit with and without meal)1.
|
Control | Stanol | ||||||
|---|---|---|---|---|---|---|---|
| Total | Biscuit with meal | Biscuit without meal | |||||
| ( | ( | ( | |||||
| Value | Mean difference from control3 | Value | Mean difference from control3 | Value | Mean difference from control3 | ||
| Total Cholesterol, mmol/L | |||||||
| Baseline | 6.01 ± 0.62 | 6.02 ± 0.78 | 0.02 ± 0.12 | 6.26 ± 0.74 | 0.25 ± 0.14 | 5.72 ± 0.73 | −0.29 ± 0.15 |
| 4 weeks | 6.11 ± 0.69 | 5.81 ± 0.72a,∗∗ | −0.30 ± 0.13 | 5.93 ± 0.70a | −0.18 ± 0.15 | 5.66 ± 0.73** | −0.45 ± 0.16 |
| Difference from baseline2 | 0.11 ± 0.47 | −0.21 ± 0.63** | −0.31 ± 0.10 | −0.33 ± 0.55** | −0.43 ± 0.11 | −0.06 ± 0.71 | −0.17 ± 0.15 |
| % change from baseline2 | 2.0 ± 7.7 | −2.9 ± 10.6** | −4.81 ± 1.70 | −4.9 ± 8.4** | −6.80 ± 1.72 | −0.4 ± 12.8 | −2.30 ± 2.68 |
|
| |||||||
| LDL Cholesterol, mmol/L | |||||||
| Baseline | 4.13 ± 0.60 | 4.12 ± 0.75 | −0.00 ± 0.12 | 4.37 ± 0.74 | 0.24 ± 0.14 | 3.81 ± 0.65 | −0.31 ± 0.14 |
| 4 weeks | 4.14 ± 0.68 | 3.87 ± 0.64a,∗∗ | −0.27 ± 0.12 | 3.97 ± 0.68a | −0.17 ± 0.15 | 3.73 ± 0.57** | −0.41 ± 0.15 |
| Difference from baseline2 | 0.01 ± 0.48 | −0.26 ± 0.50** | −0.27 ± 0.09 | −0.40 ± 0.37** | −0.41 ± 0.10 | −0.08 ± 0.58 | −0.09 ± 0.12 |
| % change from baseline2 | 0.7 ± 11.5 | −5.4 ± 12.1** | −6.06 ± 2.16 | −8.9 ± 8.3** | −9.61 ± 2.07 | −0.9 ± 14.6 | −1.56 ± 2.94 |
|
| |||||||
| HDL Cholesterol, mmol/L | |||||||
| Baseline | 1.59 ± 0.46 | 1.58 ± 0.34 | −0.01 ± 0.07 | 1.56 ± 0.32 | −0.03 ± 0.08 | 1.62 ± 0.37 | 0.03 ± 0.10 |
| 4 weeks | 1.64 ± 0.45a | 1.63 ± 0.41 | −0.01 ± 0.08 | 1.62 ± 0.39 | −0.03 ± 0.09 | 1.64 ± 0.44 | 0.00 ± 0.10 |
| Difference from baseline2 | 0.05 ± 0.17 | 0.04 ± 0.17 | −0.01 ± 0.03 | 0.06 ± 0.13 | 0.00 ± 0.03 | 0.03 ± 0.22 | −0.03 ± 0.04 |
| % change from baseline2 | 4.1 ± 9.94 | 2.5 ± 10.8 | −1.54 ± 1.90 | 3.2 ± 8.7 | −0.90 ± 2.07 | 1.8 ± 13.0 | −2.35 ± 2.87 |
|
| |||||||
| Ratio LDL/HDL cholesterol | |||||||
| Baseline | 2.84 ± 0.97 | 2.74 ± 0.80 | −0.10 ± 0.16 | 2.93 ± 0.81 | 0.09 ± 0.20 | 2.49 ± 0.74 | −0.35 ± 0.19 |
| 4 weeks | 2.75 ± 1.01 | 2.52 ± 0.73a | −0.23 ± 0.16 | 2.60 ± 0.77a | −0.15 ± 0.20 | 2.42 ± 0.67 | −0.34 ± 0.19 |
| Difference from baseline2 | −0.09 ± 0.33 | −0.22 ± 0.33* | −0.13 ± 0.06 | −0.33 ± 0.26** | −0.24 ± 0.07 | −0.07 ± 0.37 | 0.01 ± 0.08 |
| % change from baseline2 | −2.9 ± 11.1 | −7.1 ± 12.4* | −4.25 ± 2.16 | −11.4 ± 8.4** | −8.48 ± 2.23 | −1.8 ± 14.6 | 1.12 ± 3.20 |
|
| |||||||
| Triglyceride, mmol/L | |||||||
| Baseline | 1.40 ± 0.69 | 1.37 ± 0.56 | −0.03 ± 0.12 | 1.33 ± 0.59 | −0.07 ± 0.14 | 1.42 ± 0.52 | 0.02 ± 0.15 |
| 4 week | 1.32 ± 0.60 | 1.31 ± 0.78 | −0.01 ± 0.13 | 1.33 ± 0.95 | 0.00 ± 0.16 | 1.28 ± 0.50 | −0.04 ± 0.13 |
| Difference from baseline2 | −0.08 ± 0.54 | −0.06 ± 0.51 | −0.01 ± 0.10 | −0.01 ± 0.61 | 0.07 ± 0.12 | −0.14 ± 0.32 | −0.06 ± 0.11 |
| % change from baseline2 | 3.5 ± 50.9 | −3.4 ± 28.4 | −6.86 ± 7.57 | −0.6 ± 32.2 | −4.03 ± 9.79 | −7.0 ± 22.7 | −10.45 ± 10.42 |
1Values are means ± SD. To convert cholesterol and triglyceride vales to mg/dL, multiply by 38.67 and 88.57, respectively.
2Percentage change is based on individual data, (4 weeks-baseline)/baseline × 100.
3Mean Difference is the mean difference between intervention and control group, comparison between groups by independent samples t-test.
a P < 0.05, significant change over time comparing to baseline.
* P < 0.01, significantly different from control; ** P < 0.05, significantly different from control.
Change in serum liver function test between control and stanol groups1.
| ALT | GGT | |||||
|---|---|---|---|---|---|---|
| Baseline | 4 weeks | % change2 | Baseline | 4 weeks | % change2 | |
| Total subjects | ||||||
| Control ( | 19.05 ± 15.93 | 22.28 ± 13.58a | 27.9 ± 40.5 | 30.68 ± 28.07 | 35.60 ± 36.03b | 12.1 ± 24.0 |
| Stanol ( | 18.47 ± 9.78 | 22.54 ± 13.62a | 27.4 ± 57.3 | 40.32 ± 43.05 | 47.20 ± 59.23b | 16.3 ± 48.2 |
| Subjects who have normal baseline liver function test | ||||||
| Control (n = 51) | 15.00 ± 6.73 | 18.65 ± 9.66a | 27.4 ± 35.2 | 21.41 ± 11.10 | 23.37 ± 12.81b | 9.3 ± 20.7 |
| Stanol ( | 15.86 ± 7.25 | 20.23 ± 11.58a | 32.1 ± 63.9 | 24.23 ± 11.58 | 29.11 ± 23.51b | 15.8 ± 44.9 |
1Values are means ± SD. ALT: L-alanne aminotransferase (normal values of ALT: 5–40 U/L); GGT: gamma-glutamyltransferase (normal values of GGT for Male: 10–71 U/L, Female: 6–42 U/L).
2Percentage change is based on individual data, (4 weeks-baseline)/baseline × 100.
a P < 0.01, significant change over time comparing to baseline of ALT.
b P < 0.01, significant change over time comparing to baseline of GGT.